
Global Non-steroidal Anti-inflammatory Drugs (NSAID) Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Non-steroidal Anti-inflammatory Drugs (NSAID) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Non-steroidal Anti-inflammatory Drugs (NSAID) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Non-steroidal Anti-inflammatory Drugs (NSAID) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Non-steroidal Anti-inflammatory Drugs (NSAID) market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Non-steroidal Anti-inflammatory Drugs (NSAID) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Non-steroidal Anti-inflammatory Drugs (NSAID) market include Merck Animal Health, Bayer, Zoetis, St. Joseph, Merial, Generic, Elanco, Ecotrin and Boehringer Ingelheim, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Non-steroidal Anti-inflammatory Drugs (NSAID), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Non-steroidal Anti-inflammatory Drugs (NSAID), also provides the sales of main regions and countries. Of the upcoming market potential for Non-steroidal Anti-inflammatory Drugs (NSAID), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Non-steroidal Anti-inflammatory Drugs (NSAID) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Non-steroidal Anti-inflammatory Drugs (NSAID) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Non-steroidal Anti-inflammatory Drugs (NSAID) sales, projected growth trends, production technology, application and end-user industry.
Non-steroidal Anti-inflammatory Drugs (NSAID) Segment by Company
Merck Animal Health
Bayer
Zoetis
St. Joseph
Merial
Generic
Elanco
Ecotrin
Boehringer Ingelheim
Non-steroidal Anti-inflammatory Drugs (NSAID) Segment by Type
Propionic acid derivatives
Sulfonanilides
Anthranilic acid derivatives (Fenamates)
Salicylates
Enolic acid (Oxicam) derivatives
Selective COX-2 inhibitors (Coxibs)
Acetic acid derivatives
Non-steroidal Anti-inflammatory Drugs (NSAID) Segment by Application
Human
Animals
Others
Non-steroidal Anti-inflammatory Drugs (NSAID) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Non-steroidal Anti-inflammatory Drugs (NSAID) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Non-steroidal Anti-inflammatory Drugs (NSAID) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Non-steroidal Anti-inflammatory Drugs (NSAID) significant trends, drivers, influence factors in global and regions.
6. To analyze Non-steroidal Anti-inflammatory Drugs (NSAID) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-steroidal Anti-inflammatory Drugs (NSAID) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Non-steroidal Anti-inflammatory Drugs (NSAID) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-steroidal Anti-inflammatory Drugs (NSAID).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Non-steroidal Anti-inflammatory Drugs (NSAID) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Non-steroidal Anti-inflammatory Drugs (NSAID) industry.
Chapter 3: Detailed analysis of Non-steroidal Anti-inflammatory Drugs (NSAID) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Non-steroidal Anti-inflammatory Drugs (NSAID) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Non-steroidal Anti-inflammatory Drugs (NSAID) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Non-steroidal Anti-inflammatory Drugs (NSAID) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Non-steroidal Anti-inflammatory Drugs (NSAID) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Non-steroidal Anti-inflammatory Drugs (NSAID) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Non-steroidal Anti-inflammatory Drugs (NSAID) market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Non-steroidal Anti-inflammatory Drugs (NSAID) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Non-steroidal Anti-inflammatory Drugs (NSAID) market include Merck Animal Health, Bayer, Zoetis, St. Joseph, Merial, Generic, Elanco, Ecotrin and Boehringer Ingelheim, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Non-steroidal Anti-inflammatory Drugs (NSAID), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Non-steroidal Anti-inflammatory Drugs (NSAID), also provides the sales of main regions and countries. Of the upcoming market potential for Non-steroidal Anti-inflammatory Drugs (NSAID), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Non-steroidal Anti-inflammatory Drugs (NSAID) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Non-steroidal Anti-inflammatory Drugs (NSAID) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Non-steroidal Anti-inflammatory Drugs (NSAID) sales, projected growth trends, production technology, application and end-user industry.
Non-steroidal Anti-inflammatory Drugs (NSAID) Segment by Company
Merck Animal Health
Bayer
Zoetis
St. Joseph
Merial
Generic
Elanco
Ecotrin
Boehringer Ingelheim
Non-steroidal Anti-inflammatory Drugs (NSAID) Segment by Type
Propionic acid derivatives
Sulfonanilides
Anthranilic acid derivatives (Fenamates)
Salicylates
Enolic acid (Oxicam) derivatives
Selective COX-2 inhibitors (Coxibs)
Acetic acid derivatives
Non-steroidal Anti-inflammatory Drugs (NSAID) Segment by Application
Human
Animals
Others
Non-steroidal Anti-inflammatory Drugs (NSAID) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Non-steroidal Anti-inflammatory Drugs (NSAID) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Non-steroidal Anti-inflammatory Drugs (NSAID) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Non-steroidal Anti-inflammatory Drugs (NSAID) significant trends, drivers, influence factors in global and regions.
6. To analyze Non-steroidal Anti-inflammatory Drugs (NSAID) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-steroidal Anti-inflammatory Drugs (NSAID) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Non-steroidal Anti-inflammatory Drugs (NSAID) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-steroidal Anti-inflammatory Drugs (NSAID).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Non-steroidal Anti-inflammatory Drugs (NSAID) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Non-steroidal Anti-inflammatory Drugs (NSAID) industry.
Chapter 3: Detailed analysis of Non-steroidal Anti-inflammatory Drugs (NSAID) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Non-steroidal Anti-inflammatory Drugs (NSAID) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Non-steroidal Anti-inflammatory Drugs (NSAID) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
193 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2020-2031)
- 1.2.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume (2020-2031)
- 1.2.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Non-steroidal Anti-inflammatory Drugs (NSAID) Market Dynamics
- 2.1 Non-steroidal Anti-inflammatory Drugs (NSAID) Industry Trends
- 2.2 Non-steroidal Anti-inflammatory Drugs (NSAID) Industry Drivers
- 2.3 Non-steroidal Anti-inflammatory Drugs (NSAID) Industry Opportunities and Challenges
- 2.4 Non-steroidal Anti-inflammatory Drugs (NSAID) Industry Restraints
- 3 Non-steroidal Anti-inflammatory Drugs (NSAID) Market by Company
- 3.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Company Revenue Ranking in 2024
- 3.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Revenue by Company (2020-2025)
- 3.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Company (2020-2025)
- 3.4 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Average Price by Company (2020-2025)
- 3.5 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Company Ranking (2023-2025)
- 3.6 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Company Manufacturing Base and Headquarters
- 3.7 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Company Product Type and Application
- 3.8 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Non-steroidal Anti-inflammatory Drugs (NSAID) Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Non-steroidal Anti-inflammatory Drugs (NSAID) Market by Type
- 4.1 Non-steroidal Anti-inflammatory Drugs (NSAID) Type Introduction
- 4.1.1 Propionic acid derivatives
- 4.1.2 Sulfonanilides
- 4.1.3 Anthranilic acid derivatives (Fenamates)
- 4.1.4 Salicylates
- 4.1.5 Enolic acid (Oxicam) derivatives
- 4.1.6 Selective COX-2 inhibitors (Coxibs)
- 4.1.7 Acetic acid derivatives
- 4.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Type
- 4.2.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Type (2020-2031)
- 4.2.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume Share by Type (2020-2031)
- 4.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Type
- 4.3.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Type (2020-2031)
- 4.3.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type (2020-2031)
- 5 Non-steroidal Anti-inflammatory Drugs (NSAID) Market by Application
- 5.1 Non-steroidal Anti-inflammatory Drugs (NSAID) Application Introduction
- 5.1.1 Human
- 5.1.2 Animals
- 5.1.3 Others
- 5.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Application
- 5.2.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Application (2020-2031)
- 5.2.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume Share by Application (2020-2031)
- 5.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Application
- 5.3.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Application (2020-2031)
- 5.3.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application (2020-2031)
- 6 Non-steroidal Anti-inflammatory Drugs (NSAID) Regional Sales and Value Analysis
- 6.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Region (2020-2031)
- 6.2.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Region: 2020-2025
- 6.2.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Region (2026-2031)
- 6.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Region (2020-2031)
- 6.4.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Region: 2020-2025
- 6.4.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Region (2026-2031)
- 6.5 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2020-2031)
- 6.6.2 North America Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2020-2031)
- 6.7.2 Europe Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2020-2031)
- 6.9.2 South America Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Country, 2024 VS 2031
- 7 Non-steroidal Anti-inflammatory Drugs (NSAID) Country-level Sales and Value Analysis
- 7.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Country (2020-2031)
- 7.3.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Country (2020-2025)
- 7.3.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Country (2026-2031)
- 7.4 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Country (2020-2031)
- 7.4.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Country (2020-2025)
- 7.4.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.9.2 France Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.16.2 China Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.19.2 India Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Merck Animal Health
- 8.1.1 Merck Animal Health Comapny Information
- 8.1.2 Merck Animal Health Business Overview
- 8.1.3 Merck Animal Health Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Merck Animal Health Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
- 8.1.5 Merck Animal Health Recent Developments
- 8.2 Bayer
- 8.2.1 Bayer Comapny Information
- 8.2.2 Bayer Business Overview
- 8.2.3 Bayer Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Bayer Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
- 8.2.5 Bayer Recent Developments
- 8.3 Zoetis
- 8.3.1 Zoetis Comapny Information
- 8.3.2 Zoetis Business Overview
- 8.3.3 Zoetis Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Zoetis Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
- 8.3.5 Zoetis Recent Developments
- 8.4 St. Joseph
- 8.4.1 St. Joseph Comapny Information
- 8.4.2 St. Joseph Business Overview
- 8.4.3 St. Joseph Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2020-2025)
- 8.4.4 St. Joseph Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
- 8.4.5 St. Joseph Recent Developments
- 8.5 Merial
- 8.5.1 Merial Comapny Information
- 8.5.2 Merial Business Overview
- 8.5.3 Merial Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Merial Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
- 8.5.5 Merial Recent Developments
- 8.6 Generic
- 8.6.1 Generic Comapny Information
- 8.6.2 Generic Business Overview
- 8.6.3 Generic Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Generic Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
- 8.6.5 Generic Recent Developments
- 8.7 Elanco
- 8.7.1 Elanco Comapny Information
- 8.7.2 Elanco Business Overview
- 8.7.3 Elanco Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Elanco Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
- 8.7.5 Elanco Recent Developments
- 8.8 Ecotrin
- 8.8.1 Ecotrin Comapny Information
- 8.8.2 Ecotrin Business Overview
- 8.8.3 Ecotrin Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Ecotrin Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
- 8.8.5 Ecotrin Recent Developments
- 8.9 Boehringer Ingelheim
- 8.9.1 Boehringer Ingelheim Comapny Information
- 8.9.2 Boehringer Ingelheim Business Overview
- 8.9.3 Boehringer Ingelheim Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Boehringer Ingelheim Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
- 8.9.5 Boehringer Ingelheim Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Non-steroidal Anti-inflammatory Drugs (NSAID) Value Chain Analysis
- 9.1.1 Non-steroidal Anti-inflammatory Drugs (NSAID) Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Mode & Process
- 9.2 Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Non-steroidal Anti-inflammatory Drugs (NSAID) Distributors
- 9.2.3 Non-steroidal Anti-inflammatory Drugs (NSAID) Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.